TP53 and endometrial cancer: Various biomarkers [176], such as mTOR pathway disruptions, loss of estrogen and progesterone nuclear expression, TP53 mutation, changes in Wnt-signaling, or L1CAM expression, were identified as a link to endometrial cancer development [177].